1. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up. Issue 10 (13th January 2015) Authors: Cortes, Jorge E.; Kantarjian, Hagop M.; Rea, Delphine; Wetzler, Meir; Lipton, Jeffrey H.; Akard, Luke; Khoury, H. Jean; Michallet, Mauricette; Guerci‐Bresler, Agnès; Chuah, Charles; Hellmann, Andrzej; Digumarti, Raghunadharao; Parikh, Purvish M.; Legros, Laurence; Warzocha, Krzysztof; Baccarani, ... Journal: Cancer Issue: Volume 121:Issue 10(2015) Page Start: 1637 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Issue 3 (3rd March 2016) Authors: Akard, Luke; Kantarjian, Hagop M.; Nicolini, Franck E.; Wetzler, Meir; Lipton, Jeffrey H.; Baccarani, Michele; Jean Khoury, H.; Kurtin, Sandra; Li, Elizabeth; Munteanu, Mihaela; Cortes, Jorge Journal: Leukemia & lymphoma Issue: Volume 57:Issue 3(2016:Mar.) Page Start: 654 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Issue 1 (January 2015) Authors: Khoury, H. Jean; Cortes, Jorge; Baccarani, Michele; Wetzler, Meir; Masszi, Tamas; Digumarti, Raghunadharao; Craig, Adam; Benichou, Annie-Claude; Akard, Luke Journal: Leukemia & lymphoma Issue: Volume 56:Issue 1(2015:Jan.) Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗